ai
Doctors Rapidly Adopt Free AI Chatbot Backed by Peer-Reviewed Medical Literature
Physicians across the United States have quickly embraced OpenEvidence, a free AI-powered chatbot that draws on peer-reviewed medical literature. Daniel Nadler, chief executive officer of OpenEvidence, said the advertising model that has driven its growth may not suit the company's long-term plans. The comments came during an appearance at a major technology conference earlier this year.
May 13, 11:00 AM·1m read1 source
Nbc NewsAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
Doctors across America are rapidly adopting OpenEvidence, a free AI-powered chatbot that relies on peer-reviewed literature to answer medical questions. , on March 18. Nadler said the model that made OpenEvidence ubiquitous — free for doctors, paid for by ads from pharmaceutical companies and others — may not be the one that the company wants to take into the future.
The article detailing Nadler's remarks was published on May 13, 2026, at 5:30 AM EDT. It was written by Jared Perlo. A photo of Daniel Nadler at the conference was taken by David Paul Morris / Bloomberg via Getty Images.
Nadler spoke as adoption of the tool continued to accelerate among physicians nationwide. OpenEvidence operates as a free resource for medical professionals while generating revenue through advertising. The company has not detailed what alternative approaches it may pursue beyond the current ad-supported structure.
“the model that made OpenEvidence ubiquitous — free for doctors, paid for by ads from pharmaceutical companies and others”
“— Daniel Nadler, chief executive officer of OpenEvidence @NBCNews reported that the chatbot's reliance on peer-reviewed literature has contributed to its appeal among doctors seeking quick access to evidence-based answers. Nadler's appearance at the Nvidia GTC conference occurred as artificial intelligence tools increasingly intersect with clinical practice. The executive's comments signal potential shifts ahead for a platform that has gained traction without charging users directly. OpenEvidence has not announced specific changes to its business model.”
